After recent evaluations, the price target for Larimar Therapeutics (NasdaqGM:LRMR) has surged to 22.18 per share, marking a remarkable 75.76% increase from the previous estimate of 12.62 disclosed on January 16, 2024. The revised target, averaging insights from numerous analysts, spans from a low of 10.10 to a high of 28.35 per share. This upward trend signals an 83.04% surge from the latest reported closing value of 12.12 per share.
Positive Fund Sentiment Magnetizes Investors
Reveling in the glow of positivity, Larimar Therapeutics has garnered the attention of 160 funds or institutions who have embraced positions in the company. This surge in ownership represents a 2.56% increase in the last quarter, with an average portfolio weight dedicated to LRMR climbing to 0.08%, marking an impressive 37.19% boost. Noteworthy is the surge in total institutional shares, climbing by 9.97% over three months to a substantial 43,281K shares. The auspicious put/call ratio of LRMR standing at 0.28 validates the upbeat market outlook.
Insight into Shareholder Activity
Bearing the standard for significant ownership is Deerfield Management Company, L.P., proudly holding 16,941K shares, equivalent to a substantial 26.62% stake in the enterprise. On the flip side, there have been no recent adjustments in their stake. Blue Owl Capital Holdings and CHI Advisors follow closely, each clutching 3,414K shares amounting to a solid 5.37% ownership fraction. Contrarily, Verition Fund Management has trimmed its ownership share to 2,811K shares, constituting a 4.42% interest in the firm. This withdrawal marked a 3.18% decrease, with the portfolio allocation evident of a significant 26.22% decline over the quarter.
Janus Henderson Group has surged in their ownership to 2,641K shares capturing a 4.15% stake in the company. Their prior filing reported holding 2,461K shares, reflecting an encouraging 6.80% surge in ownership. However, their portfolio allocation in LRMR dwindled by 63.02% over the last quarter.
A Glimpse into Larimar Therapeutics
Defined as a clinical-stage biotechnology powerhouse, Larimar Therapeutics, Inc. is on a relentless pursuit to develop treatments for intricate rare diseases. At the heart of their offerings lies the lead compound, CTI-1601, currently undergoing scrutiny in a Phase 1 clinical program within the U.S. with promising prospects as a plausible FA treatment. The company’s ambitious agenda includes leveraging its intracellular delivery platform to craft other fusion proteins targeting additional rare diseases exhibiting deficiencies in intracellular bioactive compounds.
Fintel emerges as a beacon of hope and enlightenment in the investing landscape, serving as a comprehensive research haven for individual investors, traders, financial advisors, and small hedge funds globally. The platform’s extensive data bouquet spans fundamentals, analyst reports, ownership figures, fund sentiment, options analytics, insider trading insights, options trading trends, and beyond. Rounding off its offerings are exclusive stock selections powered by state-of-the-art, backtested quantitative models designed for bolstering returns.
Embark on a journey to discover more about this riveting tale on Fintel.
Please note that the sentiments expressed in this article reflect the author’s perspective and may not necessarily mirror those of Nasdaq, Inc.
